Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.17 - $6.17 $4.99 Million - $9.71 Million
-1,574,538 Reduced 32.85%
3,218,382 $12.2 Million
Q1 2022

May 16, 2022

SELL
$4.16 - $13.72 $4.28 Million - $14.1 Million
-1,029,684 Reduced 17.68%
4,792,920 $25.8 Million
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $171,352 - $291,283
-15,822 Reduced 0.27%
5,822,604 $78.7 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $1.01 Million - $1.46 Million
77,353 Added 1.34%
5,838,426 $105 Million
Q2 2021

Aug 16, 2021

SELL
$16.52 - $20.4 $1.61 Million - $1.98 Million
-97,243 Reduced 1.66%
5,761,073 $98.9 Million
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $13.2 Million - $20.3 Million
-797,309 Reduced 11.98%
5,858,316 $117 Million
Q4 2020

Feb 16, 2021

BUY
$15.77 - $19.03 $15.4 Million - $18.6 Million
977,404 Added 17.21%
6,655,625 $113 Million
Q3 2020

Nov 16, 2020

BUY
$16.59 - $24.79 $8.16 Million - $12.2 Million
491,584 Added 9.48%
5,678,221 $94.2 Million
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $4.86 Million - $6.76 Million
288,236 Added 5.88%
5,186,637 $120 Million
Q1 2020

May 15, 2020

BUY
$14.47 - $27.96 $24 Million - $46.3 Million
1,657,167 Added 51.13%
4,898,401 $87.4 Million
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $51.4 Million - $74.9 Million
3,241,234 New
3,241,234 $70 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.